Vanguard Group’s Genomic Health, Inc. GHDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-2,754,343
| Closed | -$187M | – | 4183 |
|
|
2019
Q3 | $187M | Sell |
2,754,343
-73,922
| -3% | -$5.08M | 0.01% | 1371 |
|
|
2019
Q2 | $165M | Buy |
2,828,265
+305,047
| +12% | +$18.1M | 0.01% | 1473 |
|
|
2019
Q1 | $177M | Buy |
2,523,218
+186,765
| +8% | +$13.8M | 0.01% | 1420 |
|
|
2018
Q4 | $150M | Buy |
2,336,453
+184,521
| +9% | +$12.9M | 0.01% | 1429 |
|
|
2018
Q3 | $151M | Buy |
2,151,932
+337,664
| +19% | +$19.8M | 0.01% | 1574 |
|
|
2018
Q2 | $91.4M | Buy |
1,814,268
+135,314
| +8% | +$5.37M | ﹤0.01% | 1826 |
|
|
2018
Q1 | $52.5M | Buy |
1,678,954
+34
| +0% | +$1.13K | ﹤0.01% | 2048 |
|
|
2017
Q4 | $57.4M | Sell |
1,678,920
-202
| -0% | -$6.44K | ﹤0.01% | 1997 |
|
|
2017
Q3 | $53.9M | Buy |
1,679,122
+8,500
| +0.5% | +$268K | ﹤0.01% | 2006 |
|
|
2017
Q2 | $54.4M | Buy |
1,670,622
+106,452
| +7% | +$3.37M | ﹤0.01% | 1978 |
|
|
2017
Q1 | $49.3M | Buy |
1,564,170
+126,807
| +9% | +$3.75M | ﹤0.01% | 2014 |
|
|
2016
Q4 | $42.2M | Buy |
1,437,363
+45,579
| +3% | +$1.39M | ﹤0.01% | 2062 |
|
|
2016
Q3 | $40.3M | Buy |
1,391,784
+22,977
| +2% | +$640K | ﹤0.01% | 2032 |
|
|
2016
Q2 | $35.4M | Buy |
1,368,807
+42,512
| +3% | +$1.13M | ﹤0.01% | 2052 |
|
|
2016
Q1 | $32.9M | Buy |
1,326,295
+36,445
| +3% | +$1M | ﹤0.01% | 2070 |
|
|
2015
Q4 | $45.4M | Buy |
1,289,850
+42,803
| +3% | +$1.15M | ﹤0.01% | 1918 |
|
|
2015
Q3 | $26.4M | Buy |
1,247,047
+67,899
| +6% | +$1.75M | ﹤0.01% | 2163 |
|
|
2015
Q2 | $32.8M | Buy |
1,179,148
+99,305
| +9% | +$2.8M | ﹤0.01% | 2138 |
|
|
2015
Q1 | $33M | Buy |
1,079,843
+101,664
| +10% | +$3.23M | ﹤0.01% | 2116 |
|
|
2014
Q4 | $31.3M | Buy |
978,179
+4,319
| +0.4% | +$141K | ﹤0.01% | 2054 |
|
|
2014
Q3 | $27.6M | Buy |
973,860
+21,103
| +2% | +$588K | ﹤0.01% | 2085 |
|
|
2014
Q2 | $26.1M | Sell |
952,757
-242
| -0% | -$6.44K | ﹤0.01% | 2114 |
|
|
2014
Q1 | $25.1M | Buy |
952,999
+55,156
| +6% | +$1.58M | ﹤0.01% | 2110 |
|
|
2013
Q4 | $26.3M | Buy |
897,843
+30,730
| +4% | +$975K | ﹤0.01% | 2067 |
|
|
2013
Q3 | $26.5M | Buy |
867,113
+38,803
| +5% | +$1.3M | ﹤0.01% | 2015 |
|
|
2013
Q2 | $26.3M | Buy |
+828,310
| New | +$27.2M | ﹤0.01% | 1967 |
|
Vanguard Group's GHDX Position: Q4 2019 in Review
Vanguard Group sold out of Genomic Health, Inc. (GHDX) in Q4 2019, closing a stake of 2,754,343 shares — an estimated $187M sold.
Vanguard Group first reported a position in GHDX in Q2 2013 and held it in 26 quarters. The position peaked at $187M in Q3 2019. 0 funds tracked by Wall St. Rank hold GHDX as of Q4 2019.
- Vanguard Group reported no remaining Genomic Health, Inc. position as of Q4 2019 after selling out during the quarter.
- Vanguard Group sold 2,754,343 Genomic Health, Inc. shares in Q4 2019, an estimated $187M.
- Vanguard Group first reported a position in Genomic Health, Inc. in Q2 2013 and held it in 26 quarters.
- Vanguard Group's Genomic Health, Inc. position peaked at $187M in Q3 2019.
- 0 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2019.
Based on Vanguard Group's 13F filing for Q4 2019, filed 14 Feb 2020.